391 related articles for article (PubMed ID: 28265031)
21. Phage Therapy Experience at the Eliava Phage Therapy Center: Three Cases of Bacterial Persistence.
Zaldastanishvili E; Leshkasheli L; Dadiani M; Nadareishvili L; Askilashvili L; Kvatadze N; Goderdzishvili M; Kutateladze M; Balarjishvili N
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696331
[TBL] [Abstract][Full Text] [Related]
22. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1.
Riera E; Macià MD; Mena A; Mulet X; Pérez JL; Ge Y; Oliver A
J Antimicrob Chemother; 2010 Jul; 65(7):1399-404. PubMed ID: 20435779
[TBL] [Abstract][Full Text] [Related]
23. Synthesized Heparan Sulfate Competitors Attenuate Pseudomonas aeruginosa Lung Infection.
Lorè NI; Veraldi N; Riva C; Sipione B; Spagnuolo L; De Fino I; Melessike M; Calzi E; Bragonzi A; Naggi A; Cigana C
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29315274
[TBL] [Abstract][Full Text] [Related]
24. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
Imamura Y; Yanagihara K; Fukuda Y; Kaneko Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Sawa T; Wiener-Kronish JP; Kohno S
Eur Respir J; 2007 May; 29(5):965-8. PubMed ID: 17301098
[TBL] [Abstract][Full Text] [Related]
25. In Vivo Efficacy of Antimicrobials against Biofilm-Producing Pseudomonas aeruginosa.
Pawar V; Komor U; Kasnitz N; Bielecki P; Pils MC; Gocht B; Moter A; Rohde M; Weiss S; Häussler S
Antimicrob Agents Chemother; 2015 Aug; 59(8):4974-81. PubMed ID: 26055372
[TBL] [Abstract][Full Text] [Related]
26. Assessment of biofilm removal capacity of a broad host range bacteriophage JHP against Pseudomonas aeruginosa.
Shafique M; Alvi IA; Abbas Z; Ur Rehman S
APMIS; 2017 Jun; 125(6):579-584. PubMed ID: 28418081
[TBL] [Abstract][Full Text] [Related]
27. A single dose of a virulent bacteriophage vB PaeP-SaPL, rescues bacteremic mice infected with multi drug resistant Pseudomonas aeruginosa.
Alvi IA; Asif M; Ur Rehman S
Virus Res; 2021 Jan; 292():198250. PubMed ID: 33259872
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and antimicrobial effectiveness of Pseudomonas aeruginosa specific bacteriophage in a human lung in vitro model.
Shiley JR; Comfort KK; Robinson JB
Appl Microbiol Biotechnol; 2017 Nov; 101(21):7977-7985. PubMed ID: 28914348
[TBL] [Abstract][Full Text] [Related]
29. In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Morinaga Y; Yanagihara K; Nakamura S; Yamamoto K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Yamada Y; Kohno S; Kamihira S
J Antimicrob Chemother; 2008 Dec; 62(6):1326-31. PubMed ID: 18835805
[TBL] [Abstract][Full Text] [Related]
30. Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.
Leung SS; Parumasivam T; Gao FG; Carrigy NB; Vehring R; Finlay WH; Morales S; Britton WJ; Kutter E; Chan HK
Pharm Res; 2016 Jun; 33(6):1486-96. PubMed ID: 26928668
[TBL] [Abstract][Full Text] [Related]
31. A subtype of a Pseudomonas aeruginosa cystic fibrosis epidemic strain exhibits enhanced virulence in a murine model of acute respiratory infection.
Carter ME; Fothergill JL; Walshaw MJ; Rajakumar K; Kadioglu A; Winstanley C
J Infect Dis; 2010 Sep; 202(6):935-42. PubMed ID: 20704484
[TBL] [Abstract][Full Text] [Related]
32. Bacteriophages as Adjuvant to Antibiotics for the Treatment of Periprosthetic Joint Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Tkhilaishvili T; Winkler T; Müller M; Perka C; Trampuz A
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31527029
[TBL] [Abstract][Full Text] [Related]
33. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
Wright A; Hawkins CH; Anggård EE; Harper DR
Clin Otolaryngol; 2009 Aug; 34(4):349-57. PubMed ID: 19673983
[TBL] [Abstract][Full Text] [Related]
34. Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections.
Soothill J
Expert Rev Anti Infect Ther; 2013 Sep; 11(9):909-15. PubMed ID: 24053272
[TBL] [Abstract][Full Text] [Related]
35. Impairment of Pseudomonas aeruginosa Biofilm Resistance to Antibiotics by Combining the Drugs with a New Quorum-Sensing Inhibitor.
Furiga A; Lajoie B; El Hage S; Baziard G; Roques C
Antimicrob Agents Chemother; 2015 Dec; 60(3):1676-86. PubMed ID: 26711774
[TBL] [Abstract][Full Text] [Related]
36. Rhesus θ-defensin-1 (RTD-1) exhibits in vitro and in vivo activity against cystic fibrosis strains of Pseudomonas aeruginosa.
Beringer PM; Bensman TJ; Ho H; Agnello M; Denovel N; Nguyen A; Wong-Beringer A; She R; Tran DQ; Moskowitz SM; Selsted ME
J Antimicrob Chemother; 2016 Jan; 71(1):181-8. PubMed ID: 26433781
[TBL] [Abstract][Full Text] [Related]
37. Assessing Pseudomonas aeruginosa virulence and the host response using murine models of acute and chronic lung infection.
Kukavica-Ibrulj I; Facchini M; Cigana C; Levesque RC; Bragonzi A
Methods Mol Biol; 2014; 1149():757-71. PubMed ID: 24818948
[TBL] [Abstract][Full Text] [Related]
38. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence.
Bragonzi A; Paroni M; Nonis A; Cramer N; Montanari S; Rejman J; Di Serio C; Döring G; Tümmler B
Am J Respir Crit Care Med; 2009 Jul; 180(2):138-45. PubMed ID: 19423715
[TBL] [Abstract][Full Text] [Related]
39. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
Stockmann C; Hillyard B; Ampofo K; Spigarelli MG; Sherwin CM
Expert Rev Respir Med; 2015 Feb; 9(1):13-22. PubMed ID: 25417708
[TBL] [Abstract][Full Text] [Related]
40. [Improving the management of chronic
She DY
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):733-735. PubMed ID: 35927042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
